% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Hammes:856060,
author = {Hammes, Jochen and Drzezga, Alexander and van Eimeren,
Thilo},
title = {{T}he {R}ole of {T}au {I}maging in {P}arkinsonian
{D}isorders},
journal = {Current neurology and neuroscience reports},
volume = {18},
number = {12},
issn = {1534-6293},
address = {Philadelphia, Pa.},
publisher = {Current Science Inc.},
reportid = {FZJ-2018-05725},
pages = {86},
year = {2018},
abstract = {Purpose of ReviewDifferential diagnosis of atypical
Parkinson syndromes (APS) is difficult as clinical
presentations may vary and as there is a strong overlap
between disease entities. Aggregations of misfolded and
hyperphosphorylated tau proteins are the common denominator
of many of these diseases.Recent FindingsSeveral tau
targeting positron emission tomography (PET) tracers have
been evaluated as possible biomarkers in APS in the recent
years. For Parkinson’s disease, dementia with Lewy bodies,
progressive supranuclear palsy, and corticobasal
degeneration, promising results have been reported with
regard to the ability to detect the presence of disease and
to discriminate patients from controls. However, the
discussion about the specificity of the first-generation
radiotracers and their value in the clinical context is
ongoing.SummaryA combined interpretation of signal strength
and distribution pattern in PET scans with first- and
second-generation tracers may be helpful in clinical
diagnosis and follow-up of patients with APS},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30293094},
UT = {WOS:000446537500003},
doi = {10.1007/s11910-018-0898-3},
url = {https://juser.fz-juelich.de/record/856060},
}